Altimmune, Inc. logo

Altimmune, Inc.

NASDAQ:ALT

Overview | Financials
Company Name Altimmune, Inc.
Symbol ALT
Currency USD
Price 7.88
Market Cap 560,038,692
Dividend Yield 0%
52-week-range 2.09 - 14.84
Industry Biotechnology
Sector Healthcare
CEO Dr. Vipin K. Garg Ph.D.
Website https://altimmune.com

An error occurred while fetching data.

About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is

Related Stocks

Kamada Ltd. logo

Kamada Ltd.

KMDA

4.23 USD

XOMA Corporation logo

XOMA Corporation

XOMA

28.98 USD

Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc.

NVCT

6.67 USD

G1 Therapeutics, Inc. logo

G1 Therapeutics, Inc.

GTHX

7.15 USD

Alpha Teknova, Inc. logo

Alpha Teknova, Inc.

TKNO

4.4 USD

Semler Scientific, Inc. logo

Semler Scientific, Inc.

SMLR

25.92 USD

Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc.

TRDA

15 USD

Accuray Incorporated logo

Accuray Incorporated

ARAY

2.19 USD

Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc.

STRO

4.5 USD

Financials

Numbers are in millions USD

Numbers are in millions USD